Otonomy Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Back to JobsResults from three clinical trials expected in 2020 including the Phase 3 trial of OTIVIDEX™ in Ménière’s disease Broadest pipeline in neurotology field expanded to include gene therapy collaboration targeting most common cause of congenital hearing loss Current capital funds operations into 2021
Apply Now